OTC Monograph Reform Could ‘Unlock’ Innovations In Three Years
This article was originally published in The Rose Sheet
Executive Summary
Following enactment of US OTC monograph reform, drug companies will unleash formulation innovations after keeping a lid on monograph R&D, CHPA anticipates. "A lot of companies have ideas like this they’ve kind of put in a drawer, that we think this is gonna unlock,” says David Spangler, an executive with the OTC trade group.
You may also be interested in...
Pediatric Provision Moves OTC Monograph Reform To Subcommittee Vote
An updated draft includes a provision requiring FDA to report annually to the Energy and Commerce Committee and to the Senate HELP Committee on the agency's evaluation of the cough and cold monograph to determine whether to impose more stringent limits on formulations allowed for use by children under age 6.
CB Fleet voluntarily recalls OTC OSP
CB Fleet, maker of the lone OTC oral sodium phosphate product, voluntarily recalls its Fleet Phospho-soda products following FDA's safety alert on the kidney injury risks associated with using the products for bowel cleansing. The recall "is directed to retailers and wholesalers" and Fleet decided "voluntarily to remove them from the market as expeditiously as possible," the Lynchburg, Va.-based firm says Dec. 11, referencing FDA's alert (1"The Tan Sheet" Dec. 15, 2008, p. 8). Fleet requests that consumers not purchase the OTC products for bowel cleansing and says to contact physicians for alternatives if an OTC is doctor-recommended
FDA Amends OTC Oral Sodium Phosphate Labeling, Warns Of Risks
FDA recommends consumers not use OTC oral sodium phosphate for bowel cleansing and says it will amend labeling for the products because of a risk of serious kidney injuries